SCYX

SCYNEXISF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

Current thesis

Composite grade F from latest DB weights. Momentum 20.8 / Value 41.1

Posture

Defensive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta +0.1.

What can break

Mixed signals. Wait for cleaner trend confirmation.

Momentum

Value

Sentiment

N/A

Setup hits (3d)

0 · Net Neutral

AI TargetsBase - · Bull - · Bear -

Data freshness

Prices

As of 2026-06-02

Fundamentals

As of 2026-05-29 • Vendor: Data Vendor v1

Scores

As of 2026-06-02 • Model: HYBRID_IC_RP

AI Memo

Unavailable: No memo yet

Investment thesis

As of 2026-06-02

Supporting evidence

What

Grade F · Defensive

Confidence Medium · Net Neutral

Target $3.67

Why

Momentum21 · Δ7d -

Value41 · Δ7d +0.1

SentimentN/A · Δ7d -

So what

Weak posture (Net Neutral). Prioritize risk control and patience.

Lead driver: Value · See fundamentals

Momentum

52% active weight

Current posture

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Value

48% active weight

Current posture

7d trendFlat

Δ7d

+0.1

Δ21d

+0.2

Sentiment

N/A

Coverage pending

No current score

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Why this grade

Composite grade F. Momentum 20.8 / Value 41.1

Fundamentals (TTM)

As of 2026-05-29

Market Cap

$448.06M

Beta

1.34

Shares Out

41.97M

P/E (TTM) · Derived

-24.3

P/S (TTM)

9.12

P/FCF (TTM) · Derived

-15.72

Rev YoY

-49.4%

EPS YoY

-198.1%

Gross Margin

+33.3%

Op Margin

-1181.1%

Net Debt

-$45.61M

Current Ratio

5.75

As of 2026-06-02 • Updated nightlySource: Internal modelMethodology